NCT05714553 2025-07-18NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNuCana plcPhase 1/2 Terminated19 enrolled
NCT05319639 2025-02-27Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabFujian Cancer HospitalPhase 1/2 Recruiting51 enrolled